All Ords drug maker's shares plunge 30% on takeover troubles

Shares in this Australian drug maker have tumbled on news a takeover bid for the company could be blocked.

| More on:

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

Key points
  • Cosette's takeover of Mayne Pharma could be block on national interest terms.
  • Cosette is already trying to get out of the deal.
  • Mayne shares fell sharply on the news.

Shares in Mayne Pharma Group Ltd (ASX: MYX) have fallen by more than 30% after it was revealed the federal government could step in to block a troubled potential takeover of the company.

US company Cosette Pharmaceuticals Inc launched a $7.40 per share takeover bid for Mayne in February, with the offer a 37% premium to the Mayne share price at the time.

But Cosette later tried to back out of the deal, arguing that there were a number of factors that constituted a "material adverse change" with regards to Mayne's business, including a trading update in April and certain correspondence with the US Food & Drug Administration (FDA).

Mayne denied Cosette's claims and took the matter to court, winning a ruling in the New South Wales Supreme Court recently, which denied Cosette's bid to back out of the deal.

Falling pills in a blue background.

Image source: Getty Images

Government could step in

But it has now emerged that Australian Treasurer Jim Chalmers could step in to block the deal on national interest terms.

Mayne told the ASX in a statement today that Mr Chalmers had written to Cosette, indicating that his "preliminary view is that the proposed acquisition would be contrary to the national interest, on the grounds that it would negatively impact the Australian economy and community".  

The statement goes on to say:

The letter states that the Treasurer is considering whether he should make orders prohibiting the acquisition contemplated by the Scheme. Treasury was advised that Cosette had re-evaluated its intentions concerning Mayne Pharma's business in Australia and determined that if Cosette were to acquire Mayne Pharma, its current intention is to seek to dispose of, or close, the manufacturing site in Adelaide.

The letter, Mayne said, went on to say that the Treasurer believed the company's Adelaide site was important to Australia's "pharmaceutical manufacturing and research and development capabilities".

Mayne said it agreed with the Treasurer regarding this view.

Given the valuable nature of the site, Mayne Pharma does not consider that it would be commercially rational to close the site and has consistently communicated this to Cosette since Cosette informed the Foreign Investment Review Board of its stated change of intention on 24 June 2025.

Mayne said the letter from the Treasurer had invited submissions from Cosette about his concerns, and the Australian company said that no final decision had been made by the Treasurer, meaning Cosette was still "obligated … to use its best endeavours to obtain the Treasurer's approval of the scheme''.

Mayne shares fell as low as $3.81 on the news before recovering to be 30.2% lower at $4.33 by mid-morning.

Motley Fool contributor Cameron England has no position in any of the stocks mentioned. The Motley Fool Australia's parent company Motley Fool Holdings Inc. has no position in any of the stocks mentioned. The Motley Fool Australia has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Scott Phillips.

More on Healthcare Shares

A group of people in a corporate setting do a collective high five.
Healthcare Shares

Up 1,173% in a year, what do 4DMedical shares have over other healthcare stocks?

Expert explains why 4DMedical is somewhat sheltered from today's sector headwinds.

Read more »

A couple sits on the bed in their hotel room wearing white robes, both have seen the bad news on their phones.
Earnings Results

What's going on with ResMed shares today?

The sleep disorder treatment company has released its third-quarter update this morning.

Read more »

A young man sits at his desk working on his laptop with a big smile on his face.
Healthcare Shares

Resmed reports double-digit revenue and profit increases in Q3 FY26

Resmed posted double-digit revenue and profit growth in Q3 FY26, with management confident about continued momentum.

Read more »

a woman puts her fingers in her ears with a pained expression on her face with her eyes closed as though trying to block hearing bad news or an unpleasant loud noise.
Healthcare Shares

Cochlear shares crashed in April, but is a comeback looming?

This ASX 200 healthcare stock is caught between short-term pain and long-term potential.

Read more »

A medical researcher rests his forehead on his fist with a dejected look on his face while sitting behind a scientific microscope with another researcher's hand on his shoulder, as if giving comfort.
Healthcare Shares

What's making healthcare the worst sector on the ASX 200, down 39% in a year?

An expert outlines the key headwinds weighing on the industry and share prices today.

Read more »

woman testing substance in laboratory dish, csl share price
Healthcare Shares

Good news, falling shares: What's dragging this ASX stock lower?

In biotech, strong updates don't always push the share price higher.

Read more »

A graphic showing a businessman running up a white upwards rising arrow symbolising the soaring Magellan share price today
Healthcare Shares

Guess which ASX All Ords healthcare share is rocketing 18% in Thursday's sinking market

Investors are piling into the ASX healthcare share on Thursday. But why?

Read more »

A woman sits at her computer with her chin resting on her hand as she contemplates her next potential investment.
Healthcare Shares

Mesoblast shares: Cash burn falls and Ryoncil® sales climb

Mesoblast reports higher Ryoncil® sales, improved cash management, and research milestones for the March 2026 quarter.

Read more »